We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.


9 July 2014 By Robert Cole

AbbVie, the U.S. pharma group, has retracted comments made about shareholder support for its $51 bln bid for London-listed Shire. Britain’s M&A framework is tripping up overseas predators. But the system works: it avoids legal tangles and ensures investors are treated fairly.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)